Evidence map›Paper›PMID 40682171›Full record

ArticleBiotechnology for biofuels and bioproducts2025

High-yield zeaxanthin production in Chlamydomonas reinhardtii via advanced metabolic pathway engineering.

Junhwan Jang, Thomas Baier, Jacob Sebastian Kneip, Olaf Kruse, EonSeon Jin

Abstract read
In one paragraph

Article in Biotechnology for biofuels and bioproducts, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Junhwan JangDepartment of Life Science, Research Institute for Natural Sciences, Hanyang University, Seoul, 04763, Korea.
Thomas BaierAlgae Biotechnology and Bioenergy, Faculty of Biology, Center for Biotechnology (CeBiTec), Bielefeld University, 33615, Bielefeld, Germany.
Jacob Sebastian KneipAlgae Biotechnology and Bioenergy, Faculty of Biology, Center for Biotechnology (CeBiTec), Bielefeld University, 33615, Bielefeld, Germany.
Olaf KruseAlgae Biotechnology and Bioenergy, Faculty of Biology, Center for Biotechnology (CeBiTec), Bielefeld University, 33615, Bielefeld, Germany.
EonSeon JinDepartment of Life Science, Research Institute for Natural Sciences, Hanyang University, Seoul, 04763, Korea. esjin@hanyang.ac.kr.

Funding

Basic Science Research Program funded by the Korean government NRF-2020R1A2C2011998National Research Foundation (NRF) funded by the Korean government (MSIT) No. RS-2024-00458958
6 · The paper itself

Abstract

backgroundZeaxanthin is a yellow xanthophyll naturally found in plants and algae, where it plays a crucial role in light absorption and photoprotection. In mammals, ingestion of zeaxanthin through the diet is essential as it accumulates in the retina where it absorbs excessive blue light to protect photoreceptors from photooxidative stress. Chlamydomonas reinhardtii is an established model organism for pigment biosynthesis and bioengineering. Previous studies developed double knockout mutants (dzl) using CRISPR-Cas9 to eliminate ZEP and LCYE genes, achieving zeaxanthin production up to 6.84 mg/L with medium optimization. However, these approaches have not explored additional enzyme overexpression strategies combined with advanced cultivation techniques, leaving significant potential for enhanced zeaxanthin biosynthesis unexplored.

resultsIn this study, we strategically enhanced zeaxanthin biosynthesis in C. reinhardtii by genome editing to knockout competing pathways coupled with overexpression of rate limiting enzymes and optimization of cultivation for efficient biomass accumulation. We employed the knockout of lycopene epsilon cyclase (LCYE; dL mutant), which resulted in a 2.83-fold increase in zeaxanthin levels. Additionally, knocking out zeaxanthin epoxidase (ZEP, dLZ mutant) redirected metabolic flux towards zeaxanthin biosynthesis, further enhancing its accumulation by 14.07-fold. Overexpression of β-carotene hydroxylase (CHYB, dLZ_C strains) enabled efficient hydroxylation of β-carotene and increasing zeaxanthin concentration further by1.80-fold without compromising growth. In addition, elevated acetate concentrations supported mixotrophic growth and resulted in a zeaxanthin yield of 21.68 ± 0.90 mg/L, threefold higher compared to previously reported values and a culminated 190-fold increase compared to the parental strain (UVM4) grown in standard medium.

conclusionOur study developed a zeaxanthin-producing mutant strain by integrating gene modification, gene overexpression, and culture optimization. Among various green microalgae, the engineered strain dLZ_C demonstrated notable zeaxanthin productivity, reaching 6.70 mg/L/day over a period of 3 days, suggesting its potential as a candidate for industrial production. Its improved efficiency may offer advantages for large-scale applications in microalgal-based zeaxanthin production. Additionally, these findings indicate that Chlamydomonas reinhardtii could serve as a viable and sustainable platform for biotechnological applications in the health, nutrition, and biotechnology sectors.

Indexed as

Acetate supplementChlamydomonas reinhardtiiCRISPR-Cas9Lycopene cyclaseMetabolic engineeringZeaxanthinZeaxanthin epoxidaseβ-carotene hydroxylase

Identifiers

PMID40682171
PMCPMC12273266

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.